vs

Side-by-side financial comparison of NOVANTA INC (NOVT) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

NOVANTA INC is the larger business by last-quarter revenue ($258.3M vs $197.9M, roughly 1.3× REPLIGEN CORP). NOVANTA INC runs the higher net margin — 6.8% vs 6.7%, a 0.0% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 8.5%). REPLIGEN CORP produced more free cash flow last quarter ($17.6M vs $5.1M). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 5.8%).

Novanta Inc is a global technology supplier delivering high-precision photonics, motion control, and machine vision solutions. It serves core segments including medical equipment manufacturing, advanced industrial automation, robotics, and life sciences, helping customers boost product performance and drive innovation worldwide.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

NOVT vs RGEN — Head-to-Head

Bigger by revenue
NOVT
NOVT
1.3× larger
NOVT
$258.3M
$197.9M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+5.1% gap
RGEN
13.6%
8.5%
NOVT
Higher net margin
NOVT
NOVT
0.0% more per $
NOVT
6.8%
6.7%
RGEN
More free cash flow
RGEN
RGEN
$12.4M more FCF
RGEN
$17.6M
$5.1M
NOVT
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
5.8%
NOVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NOVT
NOVT
RGEN
RGEN
Revenue
$258.3M
$197.9M
Net Profit
$17.5M
$13.3M
Gross Margin
43.8%
52.5%
Operating Margin
9.6%
9.0%
Net Margin
6.8%
6.7%
Revenue YoY
8.5%
13.6%
Net Profit YoY
6.1%
143.9%
EPS (diluted)
$0.46
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NOVT
NOVT
RGEN
RGEN
Q4 25
$258.3M
$197.9M
Q3 25
$247.8M
$188.8M
Q2 25
$241.0M
$182.4M
Q1 25
$233.4M
$169.2M
Q4 24
$238.1M
$174.1M
Q3 24
$244.4M
$154.9M
Q2 24
$235.9M
$154.1M
Q1 24
$230.9M
$151.3M
Net Profit
NOVT
NOVT
RGEN
RGEN
Q4 25
$17.5M
$13.3M
Q3 25
$10.7M
$14.9M
Q2 25
$4.5M
$14.9M
Q1 25
$21.2M
$5.8M
Q4 24
$16.5M
$-30.3M
Q3 24
$19.2M
$-654.0K
Q2 24
$13.8M
$3.3M
Q1 24
$14.7M
$2.1M
Gross Margin
NOVT
NOVT
RGEN
RGEN
Q4 25
43.8%
52.5%
Q3 25
44.8%
53.2%
Q2 25
44.3%
50.0%
Q1 25
44.7%
53.6%
Q4 24
45.5%
26.1%
Q3 24
44.7%
50.0%
Q2 24
44.0%
49.8%
Q1 24
43.5%
49.5%
Operating Margin
NOVT
NOVT
RGEN
RGEN
Q4 25
9.6%
9.0%
Q3 25
8.8%
8.9%
Q2 25
6.2%
7.6%
Q1 25
13.9%
3.9%
Q4 24
11.2%
-17.7%
Q3 24
13.3%
-5.1%
Q2 24
10.9%
1.0%
Q1 24
11.1%
1.3%
Net Margin
NOVT
NOVT
RGEN
RGEN
Q4 25
6.8%
6.7%
Q3 25
4.3%
7.9%
Q2 25
1.9%
8.2%
Q1 25
9.1%
3.4%
Q4 24
6.9%
-17.4%
Q3 24
7.9%
-0.4%
Q2 24
5.8%
2.2%
Q1 24
6.4%
1.4%
EPS (diluted)
NOVT
NOVT
RGEN
RGEN
Q4 25
$0.46
$0.24
Q3 25
$0.30
$0.26
Q2 25
$0.12
$0.26
Q1 25
$0.59
$0.10
Q4 24
$0.45
$-0.55
Q3 24
$0.53
$-0.01
Q2 24
$0.38
$0.06
Q1 24
$0.41
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NOVT
NOVT
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$380.9M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$1.3B
$2.1B
Total Assets
$1.8B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NOVT
NOVT
RGEN
RGEN
Q4 25
$380.9M
$767.6M
Q3 25
$89.2M
$748.7M
Q2 25
$109.9M
$708.9M
Q1 25
$106.0M
$697.2M
Q4 24
$114.0M
$757.4M
Q3 24
$92.7M
$784.0M
Q2 24
$98.5M
$809.1M
Q1 24
$93.5M
$780.6M
Total Debt
NOVT
NOVT
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
NOVT
NOVT
RGEN
RGEN
Q4 25
$1.3B
$2.1B
Q3 25
$801.5M
$2.1B
Q2 25
$801.4M
$2.1B
Q1 25
$769.8M
$2.0B
Q4 24
$745.7M
$2.0B
Q3 24
$742.2M
$2.0B
Q2 24
$702.0M
$2.0B
Q1 24
$681.7M
$2.0B
Total Assets
NOVT
NOVT
RGEN
RGEN
Q4 25
$1.8B
$2.9B
Q3 25
$1.5B
$2.9B
Q2 25
$1.5B
$2.9B
Q1 25
$1.4B
$2.9B
Q4 24
$1.4B
$2.8B
Q3 24
$1.4B
$2.8B
Q2 24
$1.4B
$2.9B
Q1 24
$1.4B
$2.8B
Debt / Equity
NOVT
NOVT
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NOVT
NOVT
RGEN
RGEN
Operating Cash FlowLast quarter
$8.8M
$25.7M
Free Cash FlowOCF − Capex
$5.1M
$17.6M
FCF MarginFCF / Revenue
2.0%
8.9%
Capex IntensityCapex / Revenue
1.4%
4.1%
Cash ConversionOCF / Net Profit
0.50×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$48.4M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NOVT
NOVT
RGEN
RGEN
Q4 25
$8.8M
$25.7M
Q3 25
$8.5M
$48.1M
Q2 25
$15.1M
$28.6M
Q1 25
$31.7M
$15.0M
Q4 24
$61.6M
$39.2M
Q3 24
$23.0M
$49.3M
Q2 24
$41.1M
$42.2M
Q1 24
$32.8M
$44.7M
Free Cash Flow
NOVT
NOVT
RGEN
RGEN
Q4 25
$5.1M
$17.6M
Q3 25
$4.2M
$43.4M
Q2 25
$11.7M
$21.5M
Q1 25
$27.4M
$11.4M
Q4 24
$59.3M
$33.6M
Q3 24
$19.5M
$42.3M
Q2 24
$36.2M
$37.4M
Q1 24
$26.4M
$36.4M
FCF Margin
NOVT
NOVT
RGEN
RGEN
Q4 25
2.0%
8.9%
Q3 25
1.7%
23.0%
Q2 25
4.8%
11.8%
Q1 25
11.7%
6.8%
Q4 24
24.9%
19.3%
Q3 24
8.0%
27.3%
Q2 24
15.3%
24.3%
Q1 24
11.4%
24.0%
Capex Intensity
NOVT
NOVT
RGEN
RGEN
Q4 25
1.4%
4.1%
Q3 25
1.7%
2.5%
Q2 25
1.4%
3.9%
Q1 25
1.8%
2.1%
Q4 24
0.9%
3.2%
Q3 24
1.5%
4.5%
Q2 24
2.1%
3.1%
Q1 24
2.8%
5.5%
Cash Conversion
NOVT
NOVT
RGEN
RGEN
Q4 25
0.50×
1.93×
Q3 25
0.80×
3.23×
Q2 25
3.35×
1.92×
Q1 25
1.49×
2.57×
Q4 24
3.74×
Q3 24
1.20×
Q2 24
2.99×
12.70×
Q1 24
2.24×
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons